undamentalytics Newsletter
Sign in

Capricor Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Capricor Therapeutics, Inc. had total assets of $356m, total liabilities of $50.2m and shareholders' equity of $306m. It held $288m in cash against $0 of debt: net cash of $288m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents2028636443335101511288
Total current assets1541214181681134364351163323
Goodwill——2————————————
Total assets1561416191691135415059170356
Accounts payable00———————————32
Deferred revenue (current)——04410———018241212
Total current liabilities1126752113424312136
Long-term debt————————000————
Total debt000000000033330
Total liabilities11620172355461038362550
Shareholders' equity25−1−6−1−4115728311223145306
Non-controlling interests and other (assets − liabilities − equity)−1——————————————
Net debt (negative = net cash)−2−0−2−8−6−3−6−4−4−32−32−6−11−8−288
Shares outstanding———————13m16m—24m25m31m—57m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CAPR vs JANXCAPR vs CRSPABEO vs CAPR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Capricor Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Capricor Therapeutics, Inc.